Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): A natural product recently approved for cutaneous T-cell lymphoma

Journal of Antibiotics

Volumn 64, Issue 8, 2011, Pages 525-531

  Vandermolen, Karen M ^a   McCulloch, William ^b   Pearce, Cedric J ^c   Oberlies, Nicholas H ^a  

^a UNIVERSITY OF NORTH CAROLINA AT GREENSBORO   (United States)

^b Alba BioPharma Advisors   (United States)

^c Mycosynthetix   (United States)

Author keywords

Chromobacterium violaceum; cutaneous T cell lymphoma; depsipeptide; histone deacetylase inhibitor; Istodax; romidepsin

Indexed keywords

ANTINEOPLASTIC AGENT; DEPSIPEPTIDE; GLUTATHIONE; GRANISETRON; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; NATURAL PRODUCT; ROMIDEPSIN; ROMIDEPSIN DERIVATIVE; THIOL; TRICHOSTATIN A; UNCLASSIFIED DRUG; VORINOSTAT; ZINC ION;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ANOREXIA; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; CELL CYCLE ARREST; CHEMICAL INTERACTION; CHEMOTHERAPY INDUCED EMESIS; CHROMOBACTERIUM VIOLACEUM; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; CUTANEOUS T CELL LYMPHOMA; DISULFIDE BOND; DRUG APPROVAL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG FEVER; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; ECG ABNORMALITY; FATIGUE; GRANULOCYTOPENIA; HEART ARRHYTHMIA; HUMAN; KIDNEY CARCINOMA; LEUKOPENIA; LUNG CANCER; METASTASIS; MYELODYSPLASTIC SYNDROME; NAUSEA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIDE EFFECT; ST SEGMENT DEPRESSION; T WAVE; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; BIOLOGICAL PRODUCTS; CHROMOBACTERIUM; CLINICAL TRIALS AS TOPIC; DEPSIPEPTIDES; DRUG APPROVAL; HISTONE DEACETYLASES; HUMANS; JAPAN; LYMPHOMA, T-CELL, CUTANEOUS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; SOIL MICROBIOLOGY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

CHROMOBACTERIUM VIOLACEUM; NEGIBACTERIA;

EID: 79960185557     PISSN: 00218820     EISSN: 18811469     Source Type: Journal    
DOI: 10.1038/ja.2011.35     Document Type: Review

References (75)

1. Kurdistani, S. K. Histone modifications as markers of cancer prognosis: A cellular view. Br. J. Cancer 97, 1-5 (2007). (Pubitemid 47012099)
2. Emanuele, S., Lauricella, M. & Tesoriere, G. Histone deacetylase inhibitors: Apoptotic effects and clinical implications (review). Int. J. Oncol. 33, 637-646 (2008).
3. Glaser, K. B. HDAC inhibitors: Clinical update and mechanism-based potential. Biochem. Pharmacol. 74, 659-671 (2007). (Pubitemid 47096639)
4. Zheng, Y. G., Wu, J., Chen, Z. & Goodman, M. Chemical regulation of epigenetic modifications: Opportunities for new cancer therapy. Med. Res. Rev. 28, 645-687 (2008).
5. Kuo, M. H. & Allis, C. D. Roles of histone acetyltransferases and deacetylases in gene regulation. Bioessays 20, 615-626 (1998). (Pubitemid 28422221)
6. Fukuda, H., Sano, N., Muto, S. & Horikoshi, M. Simple histone acetylation plays a complex role in the regulation of gene expression. Brief Funct. Genomic. Proteomic. 5, 190-208 (2006). (Pubitemid 46470220)
7. Mitsiades, C. S. et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications. Proc. Natl Acad. Sci. USA 101, 540-545 (2004). (Pubitemid 38084672)
8. Melnick, A. & Licht, J. D. Histone deacetylases as therapeutic targets in hematologic malignancies. Curr. Opin. Hematol. 9, 322-332 (2002). (Pubitemid 34596877)
9. Mahlknecht, U. & Hoelzer, D. Histone acetylation modifiers in the pathogenesis of malignant disease. Mol. Med. 6, 623-644 (2000).
10. Marks, P. A., Richon, V. M., Breslow, R. & Rifkind, R. A. Histone deacetylase inhibitors as new cancer drugs. Curr. Opin. Oncol. 13, 477-483 (2001). (Pubitemid 33027900)
11. Klisovic, M. I. et al. Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells. Leukemia 17, 350-358 (2003). (Pubitemid 36266913)
12. Bieliauskas, A. V. & Pflum, M. K. Isoform-selective histone deacetylase inhibitors. Chem. Soc. Rev. 37, 1402-1413 (2008).
13. Papeleu, P. et al. Differential effects of histone deacetylase inhibitors in tumor and normal cells-what is the toxicological relevance? Crit. Rev. Toxicol. 35, 363-378 (2005). (Pubitemid 40686619)
14. Dokmanovic, M. & Marks, P. A. Prospects: Histone deacetylase inhibitors. J. Cell. Biochem. 96, 293-304 (2005). (Pubitemid 41437862)
15. Ueda, H. et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J. Antibiot. 47, 301-310 (1994). (Pubitemid 24106520)
16. Xiao, J. J., Byrd, J., Marcucci, G., Grever, M. & Chan, K. K. Identification of thiols and glutathione conjugates of depsipeptide FK228 (FR901228), a novel histone protein deacetylase inhibitor, in the blood. Rapid Commun. Mass Spectrom. 17, 757-766 (2003). (Pubitemid 36433157)
17. Grant, C. et al. Romidepsin: A new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. Expert Rev. Anticancer. Ther. 10, 997-1008 (2010).
18. Willemze, R. et al. WHO-EORTC classification for cutaneous lymphomas. Blood 105, 3768-3785 (2005). (Pubitemid 40656118)
19. Whittaker, S. J., Marsden, J. R., Spittle, M. & Russell Jones, R. Joint British Association of Dermatologists and UK Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas. Br. J. Dermatol. 149, 1095-1107 (2003). (Pubitemid 38058085)
20. Litvinov, I. V., Jones, D. A., Sasseville, D. & Kupper, T. S. Transcriptional profiles predict disease outcome in patients with cutaneous T-cell lymphoma. Clin. Cancer Res. 16, 2106-2114 (2010).
21. Weinstock, M. A. & Horm, J. W. Mycosis fungoides in the United States: Increasing incidence and descriptive epidemiology. JAMA 260, 42-46 (1988).
22. Criscione, V. D. & Weinstock, M. A. Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. Arch. Dermatol. 143, 854-859 (2007). (Pubitemid 47076482)
23. Kim, E. J. et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J. Clin. Invest. 115, 798-812 (2005). (Pubitemid 40489380)
24. Lorincz, A. L. Cutaneous T-cell lymphoma (mycosis fungoides). Lancet 347, 871-876 (1996). (Pubitemid 26099542)
25. Kim, Y. H., Liu, H. L., Mraz-Gernhard, S., Varghese, A. & Hoppe, R. T. Long-term outcome of 525 patients with mycosis fungoides and Sézary syndrome: Clinical prognostic factors and risk for disease progression. Arch. Dermatol. 139, 857-866 (2003). (Pubitemid 36898920)
26. Bradford, P. T., Devesa, S. S., Anderson, W. F. & Toro, J. R. Cutaneous lymphoma incidence patterns in the United States: A population-based study of 3884 cases. Blood 113, 5064-5073 (2009).
27. Kim, Y. H., Chow, S., Varghese, A. & Hoppe, R. T. Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides. Arch. Dermatol. 135, 26-32 (1999). (Pubitemid 29069513)
28. Duvic, M. et al. Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma. J. Am. Acad. Dermatol. 49, 35-49 (2003). (Pubitemid 36801629)
29. Zackheim, H. S., Amin, S., Kashani-Sabet, M. & McMillan, A. Prognosis in cutaneous T-cell lymphoma by skin stage: Long-term survival in 489 patients. J. Am. Acad. Dermatol. 40, 418-425 (1999). (Pubitemid 29115302)
30. Siegel, R. S., Pandolfino, T., Guitart, J., Rosen, S. & Kuzel, T. M. Primary cutaneous Tcell lymphoma: Review and current concepts. J. Clin. Oncol. 18, 2908-2925 (2000). (Pubitemid 30620080)
31. Shigematsu, N. et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. II. Structure determination. J. Antibiot. 47, 311-314 (1994). (Pubitemid 24106521)
32. Manoharan, T. H., Burgess, J. A., Ho, D., Newell, C. L. & Fahl, W. E. Integration of a mutant c-Ha-ras oncogene into C3H/10T1/2 cells and its relationship to tumorigenic transformation. Carcinogenesis 6, 1295-1301 (1985). (Pubitemid 15013331)
33. Wang, R., Brunner, T., Zhang, L. & Shi, Y. Fungal metabolite FR901228 inhibits c-Myc and Fas ligand expression. Oncogene 17, 1503-1508 (1998). (Pubitemid 28472754)
34. Rajgolikar, G., Chan, K. K. & Wang, H. C. Effects of a novel antitumor depsipeptide, FR901228, on human breast cancer cells. Breast Cancer Res. Treat. 51, 29-38 (1998). (Pubitemid 28550158)
35. Nakajima, H., Kim, Y. B., Terano, H., Yoshida, M. & Horinouchi, S. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp. Cell Res. 241, 126-133 (1998). (Pubitemid 28366586)
36. Yoshida, M. et al. Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother. Pharmacol. 48(Suppl 1), S20-S26 (2001). (Pubitemid 33738367)
37. Furumai, R. et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res. 62, 4916-4921 (2002). (Pubitemid 34984414)
38. Finnin, M. S. et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401, 188-193 (1999). (Pubitemid 29436325)
39. Piekarz, R. & Bates, S. A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. Curr. Pharm. Des. 10, 2289-2298 (2004). (Pubitemid 38855037)
40. Archer, S. Y., Meng, S., Shei, A. & Hodin, R. A. p21WAF1 is required for butyratemediated growth inhibition of human colon cancer cells. Proc. Natl Acad. Sci. USA 95, 6791-6796 (1998).
41. Burgess, A. J. et al. Up-regulation of p21WAF1/CIP1 by histone deacetylase inhibitors reduces their cytotoxicity. Mol. Pharmacol. 60, 828-837 (2001). (Pubitemid 32900266)
42. Rosato, R. R., Almenara, J. A. & Grant, S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res. 63, 3637-3645 (2003). (Pubitemid 36793047)
43. Sandor, V. et al. p21-dependent G1 arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br. J. Cancer 83, 817-825 (2000).
44. Peart, M. J. et al. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res. 63, 4460-4471 (2003). (Pubitemid 36951018)
45. Insinga, A. et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat. Med. 11, 71-76 (2005). (Pubitemid 40215840)
46. Nebbioso, A. et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat. Med. 11, 77-84 (2005). (Pubitemid 40215841)
47. Yu, X. et al. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J. Natl Cancer Inst. 94, 504-513 (2002). (Pubitemid 34411289)
48. Yu, C. et al. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood 102, 3765-3774 (2003). (Pubitemid 37409399)
49. Huang, H. C., Liu, Y. C., Liu, S. H., Tzang, B. S. & Lee, W. C. Geldanamycin inhibits trichostatin A-induced cell death and histone H4 hyperacetylation in COS-7 cells. Life Sci. 70, 1763-1775 (2002).
50. Kwon, H. J., Kim, M. S., Kim, M. J., Nakajima, H. & Kim, K. W. Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis. Int. J. Cancer 97, 290-296 (2002). (Pubitemid 34049018)
51. Woo, S. et al. Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clin. Cancer Res. 15, 1496-1503 (2009).
52. Sandor, V. et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin. Cancer Res. 8, 718-728 (2002). (Pubitemid 34742100)
53. Marshall, J. L. et al. A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J. Exp. Ther. Oncol. 2, 325-332 (2002). (Pubitemid 35265981)
54. Byrd, J. C. et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 105, 959-967 (2005). (Pubitemid 40170861)
55. Fouladi, M. et al. Phase I study of depsipeptide in pediatric patients with refractory solid tumors: A Children's Oncology Group report. J. Clin. Oncol. 24, 3678-3685 (2006). (Pubitemid 46630544)
56. Klimek, V. M. et al. Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clin. Cancer Res. 14, 826-832 (2008). (Pubitemid 351231166)
57. Bates, S. E. et al. Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma. Br. J. Haematol. 148, 256-267 (2009).
58. Piekarz, R. L. et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: A case report. Blood 98, 2865-2868 (2001).
59. Piekarz, R. L. et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J. Clin. Oncol. 27, 5410-5417 (2009).
60. Piekarz, R. L. et al. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin. Cancer Res. 12, 3762-3773 (2006). (Pubitemid 44000258)
61. Whittaker, S. J. et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J. Clin. Oncol. 28, 4485-4491 (2010).
62. Odenike, O. M. et al. Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia. Clin. Cancer Res. 14, 7095-7101 (2008).
63. Whitehead, R. P. et al. Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: A Southwest Oncology Group study (S0336). Invest. New Drugs 27, 469-475 (2009).
64. Schrump, D. S. et al. Clinical and molecular responses in lung cancer patients receiving romidepsin. Clin. Cancer Res. 14, 188-198 (2008). (Pubitemid 351377995)
65. Stadler, W. M., Margolin, K., Ferber, S., McCulloch, W. & Thompson, J. A. A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin. Genitourin. Cancer 5, 57-60 (2006).
66. Molife, L. R. et al. Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC). Ann. Oncol. 21, 109-113 (2010).
67. Li, K. W., Wu, J., Xing, W. N. & Simon, J. A. Total synthesis of the antitumor depsipeptide FR-901,228. J. Am. Chem. Soc. 118, 7237-7238 (1996). (Pubitemid 26261143)
68. Greshock, T. J., Johns, D. M., Noguchi, Y. & Williams, R. M. Improved total synthesis of the potent HDAC inhibitor FK228 (FR-901228). Org. Lett. 10, 613-616 (2008).
69. Wen, S., Packham, G. & Ganesan, A. Macrolactamization versus macrolactonization: Total synthesis of FK228, the depsipeptide histone deacetylase inhibitor. J. Org. Chem. 73, 9353-9361 (2008).
70. Jones, P. & Steinkuhler, C. From natural products to small molecule ketone histone deacetylase inhibitors: Development of new class specific agents. Curr. Pharm. Des. 14, 545-561 (2008). (Pubitemid 351516878)
71. Yurek-George, A. et al. The first biologically active synthetic analogues of FK228, the depsipeptide histone deacetylase inhibitor. J. Med. Chem. 50, 5720-5726 (2007). (Pubitemid 350106026)
72. Suzuki, T. et al. Novel inhibitors of human histone deacetylases: Design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates. J. Med. Chem. 48, 1019-1032 (2005). (Pubitemid 40270446)
73. Suzuki, T. et al. Identification of a potent and stable antiproliferative agent by the prodrug formation of a thiolate histone deacetylase inhibitor. Bioorg. Med. Chem. Lett. 17, 1558-1561 (2007).
74. Mays, J. R., Restituyo, J. A., Katzenberger, R. J., Wassarman, D. A. & Rajski, S. R. Cyclic disulfides as functional mimics of the histone deacetylase inhibitor FK-228. Tetrahedron Lett. 48, 4579-4583 (2007). (Pubitemid 46818367)
75. Pro, B. et al. Final results from a pivotal, multicenter, international, open-label, phase 2 study of romidepsin in progressive or relapsed peripheral T-cell lymphoma (PTCL) following prior systemic therapy. 52nd American Society of Hematology Annual Meeting and Exposition Abstract 114 Orange County Convention Center, Orlando, FL, USA (2010).